HopeStage
Back to overview

Schizophrenia studies

Topics
More filters

Schizophrenia

Schizophrenia can affect how a person perceives reality, thinks and feels, sometimes involving hearing voices or holding unusual beliefs.

4505studies shown
Showing 2,113-2,124 of 4,505
Drug study icon
CompletedNCT03697252

Safety study of Safety and Efficacy of KarXT in schizophrenia

Official study title

A Phase 2, Randomized, Double-blinded Study to Assess the Safety, Tolerability, and Efficacy of KarXT in Hospitalized Adults With DSM-5 Schizophrenia

This study has finished and is no longer accepting participants.

Multiple locations, including Little Rock
SchizophreniaMedication studyAges 18–60
Countries
United States
Sponsor
Karuna Therapeutics, Inc., a Bristol Myers Squibb company
Drug study icon
CompletedNCT00034775

Safety study of Safety and Tolerabiltiy Associated With a Switch From Oral Antipsychotic Medications to Long-acting Injectable Risperidone in schizophrenia

Official study title

Open-Label Trial Exploring A Switching Regimen From Oral Neuroleptics, Other Than Risperidone, To Risperidone Depot Microspheres

This study has finished and is no longer accepting participants.

Location not clearly listed
SchizophreniaMedication studyAges 18+
Countries
Sponsor
Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
Drug study icon
CompletedNCT01559272

Safety study of pharmacokinetics, Safety, and Tolerability of Paliperidone Palmitate in schizophrenia

Official study title

A Single-Dose, Open-Label, Randomized, Parallel-Group Study to Assess the Pharmacokinetics, Safety, and Tolerability of a Paliperidone Palmitate 3-Month Formulation in Subjects With Schizophrenia

This study has finished and is no longer accepting participants.

Multiple locations, including Little Rock
SchizophreniaMedication studyAges 18–65
Countries
United States, Belgium, Bulgaria, + 8 others
Sponsor
Janssen Research & Development, LLC
Other study type icon
CompletedNCT02712463

Rate of Hospitalization in people with Schizophrenia Treated With Antipsychotics

Official study title

A Retrospective, Observational Study to Assess the Rate of Hospitalization in Patients With Schizophrenia Treated One Year Before With Oral Antipsychotics and One Year After With Long Acting Injectable Atypical Antipsychotics - REALAI Study

This study has finished and is no longer accepting participants.

Multiple locations, including Aracaju
SchizophreniaObservational studyAges 18–55
Countries
Brazil, Mexico
Sponsor
Janssen-Cilag Ltd.
Drug study icon
CompletedNCT00210717

A Study to Compare the Effectiveness and Safety of Flexibly Varied Doses of Paliperidone Palmitate and Risperidone in Treating people with Schizophrenia

Official study title

A Randomized, Double-Blind, Parallel Group, Comparative Study of Flexibly Dosed Paliperidone Palmitate (25, 50, 75, or 100 mg eq.) Administered Every 4 Weeks and Flexibly Dosed RISPERDAL CONSTA (25, 37.5, or 50 mg) Administered Every 2 Weeks in Subjects With Schizophrenia

This study has finished and is no longer accepting participants.

Location not clearly listed
SchizophreniaMedication studyAges 18+
Countries
Sponsor
Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
Drug study icon
CompletedNCT00645372

Ziprasidone and Risperidone for schizophrenia

What is this study about?

Researchers compared Ziprasidone and Risperidone to find out how the approaches affected psychotic symptoms in people with schizophrenia.

This study has finished and is no longer accepting participants.

Multiple locations, including Beijing
SchizophreniaMedication studyAges 18–65
Countries
China
Sponsor
Pfizer's Upjohn has merged with Mylan to form Viatris Inc.
Drug study icon
CompletedNCT01654601

A Study to Compare the Pharmacokinetics Profile of DWCZP Tablet 100mg and Clozaril® Tablet 100mg

Official study title

Clinical Trials to Compare the Pharmacokinetics Profile of DWCZP Tablet 100mg and Clozaril® Tablet 100mg After a Multi-dose Oral Administration in Schizophrenia Patients

This study has finished and is no longer accepting participants.

Multiple locations, including Choongju
SchizophreniaMedication studyAges 20–60
Countries
South Korea
Sponsor
Dong Wha Pharmaceutical Co. Ltd.
Other study type icon
CompletedNCT00392743

A Study to Compare Two Different Brain Imaging Techniques in Healthy Volunteers and in Schizophrenic Patients

Official study title

An Open-label, Cross-over Study, to Compare the PET and SPECT Measurement of Antipsychotic-induced D2 Receptor Occupancy, in a Group of Healthy Volunteers and in Another Group of Patients With Schizophrenia and Other Psychotic Disorders

This study has finished and is no longer accepting participants.

Multiple locations, including Barcelona
SchizophreniaObservational studyAges 18+
Countries
Spain
Sponsor
GlaxoSmithKline
Drug study icon
CompletedNCT03627195

Maximum Tolerated Dose of an Investigational Drug in Subjects With Schizophrenia

Official study title

A Randomized, Double Blind, Placebo Controlled, Single Ascending Dose Study With Lurasidone Injectable Suspension to Evaluate Safety, Tolerability and Pharmacokinetics in Subjects With Schizophrenia

This study has finished and is no longer accepting participants.

In Long Beach
SchizophreniaMedication studyAges 18–65
Countries
United States
Sponsor
Sumitomo Pharma America, Inc.
Drug study icon
CompletedNCT02624167

Safety, Tolerability and Efficacy NW-3509A in people with Chronic Schizophrenia

Official study title

A Phase IIA, Prospective, Randomized, Double-blind, Multiple-dose Study of NW-3509A in Chronic Schizoprhenia Patients Not Responding to Their Current Anti-psychotic Medication

This study has finished and is no longer accepting participants.

Multiple locations, including Garden Grove
SchizophreniaMedication studyAges 18–65
Countries
United States, India
Sponsor
Newron Pharmaceuticals SPA

Registry coverage

We gather information about mental health clinical trials from the public registries we index. Coverage is still expanding, so some studies may not appear yet.